Duke Comp Cancer Ctr Core Support Grant

杜克癌症中心核心支持补助金

• 批准号: 7657818
• 负责人: HERBERT KIM LYERLY
• 金额: $ 24.12万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7657818
• 关键词: American College of Surgeons Oncology Group; Antineoplastic Agents; Astatine; Award; Basic Science; Bioinformatics; Biomedical Research; Blood; Cancer Center Support Grant; Cancer Patient; Cancer and Leukemia Group B; Cell physiology; Cellular biology; Charge; Class; Clinical; Clinical Oncology; Clinical Research; Clinical Trials; Communities; DNA; Data; Development; Duke Comprehensive Cancer Center; Enrollment; Equilibrium; Fund Raising; Funding; Gene Expression; Generations; Goals; Grant; Hormone Receptor; Image; Institution; Laboratories; Life; Malignant Neoplasms; Mismatch Repair; National Cancer Institute; Operative Surgical Procedures; Organogenesis; Outcome; Patients; Population; Population Study; Program Research Project Grants; Reproduction spores; Request for Applications; Research; Research Activity; Research Infrastructure; Research Personnel; Resource Sharing; Resources; Role; Scientific Advances and Accomplishments; Signal Transduction; Societies; Source; Stem cell transplant; Stem cells; Structure; Therapeutic Clinical Trial; Tissues; U-Series Cooperative Agreements; Umbilical Cord Blood; Work; antiangiogenesis therapy; anticancer research; base; cancer risk; improved; malignant breast neoplasm; member; novel; oncology; programs; research study; statistical center

The Duke Comprehensive Cancer Center (DCCC) is charged and empowered to serve as the center of all Duke activities in cancer and to deliver the benefits of these activities to our community and society. As a matrix center continuously supported by the National Cancer Institute (NCI) for over 31 years, the DCCC leverages Duke's basic research infrastructure with clinical oncology research excellence which is enabled by treating 4,800 new cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and is enhanced by the presence of national oncology research resources, such as the data and statistical centers of two NCI-funded cooperative groups. These cancer research activities are supported by $48M in NCI funding (a $27M increase from 1998) and nearly $171M in total research funding (a $66M increase from 1998) and are coordinated by the DCCC and forty other center, SPORE and program project grants as well as cooperative agreements. In this competitive renewal application, we request support for 358 members (an increase of 68 since 1998) working in 11 Research Programs supported by 17 Shared Resources. Significant basic scientific advances have been made by DCCC investigators including: an understanding of DNA mismatch repair mechanisms, the role of Ras structure md signaling, and the generation of novel anti-cancer agents targeting hormone receptors. These advances are balanced with clinical and population studies such as the first clinical trial demonstrating a benefit of a new class of anti-cancer compounds, the anti-angiogenesis agents and the alpha emitter 211-Astatine; the development and demonstration of the use of umbilical cord blood as a source of stem cells for transplantation; and the development and demonstration of the use of gene expression array profiling to predict clinical outcomes in breast cancer. The DCCC has benefited from a five-year fund raising campaign which generated $113 million in philanthropic support, generated new laboratory and administrative space, enabled new Programs-in-Development in Organogenesis/Stem Cell Biology and Imaging, and enabled enhancement of Shared Resources such as Bioinformatics, Tissue and Blood Procurement, and Clinical Cellular Processing. This application for support of the DCCC articulates the principles, goals and strategies for propelling the DCCC to fully leverage the enormous advances in biomedical research to improve and extend the lives of cancer patients with cancer and at risk for cancer, and delivering these to society.

杜克大学综合癌症中心 (DCCC) 被授权作为所有杜克大学的中心 癌症领域的活动，并将这些活动的好处带给我们的社区和社会。作为矩阵中心 DCCC 31 年来一直得到美国国家癌症研究所 (NCI) 的持续支持，利用杜克大学的 基础研究基础设施与卓越的临床肿瘤学研究相结合，通过治疗 4,800 名新患者而得以实现 每年招募 1,000 多名癌症患者参加治疗性临床试验，并通过 国家肿瘤学研究资源的存在，例如两个 NCI 资助的数据和统计中心 合作团体。这些癌症研究活动得到 NCI 4800 万美元资金的支持（增加了 2700 万美元） 自 1998 年起）和近 1.71 亿美元的研究经费总额（比 1998 年增加了 6600 万美元），并由 DCCC 和其他 40 个中心、SPORE 和计划项目赠款以及合作协议。在这个 竞争性续约申请，我们请求为在以下领域工作的 358 名会员（自 1998 年以来增加了 68 名）提供支持： 11 个研究项目由 17 个共享资源支持。基础科学取得了重大进展 DCCC 的研究人员包括：了解 DNA 错配修复机制、Ras 结构的作用 md 信号传导，以及针对激素受体的新型抗癌药物的产生。这些进步是 与临床和人群研究相平衡，例如第一个临床试验证明了新类别的益处 抗癌化合物、抗血管生成剂和α发射体211-砹；的发展和 示范使用脐带血作为移植干细胞的来源；和发展 并演示使用基因表达阵列分析来预测乳腺癌的临床结果。这 DCCC 受益于为期五年的筹款活动，筹集了 1.13 亿美元的慈善资金 支持，创建新的实验室和行政空间，启用新的开发项目 器官发生/干细胞生物学和成像，并增强了共享资源，例如 生物信息学、组织和血液采购以及临床细胞处理。此应用程序支持 DCCC 阐明了推动 DCCC 充分利用巨大潜力的原则、目标和战略 生物医学研究的进展，以改善和延长患有癌症和有癌症风险的癌症患者的生命 癌症，并将这些传递给社会。